Invesco Ltd. Increases Position in Icon Plc $ICLR

Invesco Ltd. lifted its holdings in Icon Plc (NASDAQ:ICLR) by 3.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,085,993 shares of the medical research company’s stock after buying an additional 98,032 shares during the quarter. Invesco Ltd. owned approximately 3.82% of Icon worth $448,858,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Artisan Partners Limited Partnership grew its position in Icon by 67.4% in the 2nd quarter. Artisan Partners Limited Partnership now owns 7,184,870 shares of the medical research company’s stock valued at $1,045,039,000 after acquiring an additional 2,893,946 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Icon by 21.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company’s stock worth $545,730,000 after purchasing an additional 650,379 shares during the last quarter. Ninety One UK Ltd boosted its stake in shares of Icon by 2.6% during the second quarter. Ninety One UK Ltd now owns 2,993,652 shares of the medical research company’s stock valued at $435,427,000 after purchasing an additional 75,465 shares during the period. 1832 Asset Management L.P. grew its holdings in shares of Icon by 587.9% in the second quarter. 1832 Asset Management L.P. now owns 1,151,328 shares of the medical research company’s stock worth $167,461,000 after purchasing an additional 983,950 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Icon in the second quarter worth about $158,639,000. 95.61% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ICLR has been the subject of a number of research analyst reports. Robert W. Baird set a $220.00 price objective on shares of Icon in a report on Friday, October 24th. Rothschild Redb raised shares of Icon from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. Leerink Partners set a $220.00 price target on Icon in a report on Thursday, October 23rd. Weiss Ratings reissued a “hold (c-)” rating on shares of Icon in a research note on Monday. Finally, UBS Group set a $220.00 target price on Icon in a research report on Friday, October 24th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $205.00.

Icon Stock Performance

Shares of ICLR stock opened at $185.77 on Friday. The firm has a market cap of $15.00 billion, a price-to-earnings ratio of 25.14, a PEG ratio of 3.44 and a beta of 1.25. Icon Plc has a 52-week low of $125.10 and a 52-week high of $228.29. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company’s 50 day moving average is $175.90 and its 200 day moving average is $164.08.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.